Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | GLP1R | P43220 | 17/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468789 | 0.88 | GPR119 (0.45) | GPR119GLP1RKCNH2PDE10A | |
| SCHEMBL25289276 | 0.88 | GLP1R (0.50) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL25289275 | 0.88 | GLP1R (0.50) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL20266521 | 0.87 | GPR119 (0.56) | GPR119GLP1RHTR1ACYP2C8KCNH2 | |
| SCHEMBL29556921 | 0.87 | GPR119 (0.56) | GPR119GLP1RHTR1ACYP2C8KCNH2 | |
| SCHEMBL27111251 | 0.87 | GLP1R (0.49) | GPR119GLP1RPDE10A | |
| SCHEMBL30468802 | 0.87 | GLP1R (0.48) | GLP1R | |
| SCHEMBL30680772 | 0.85 | GPR119 (0.47) | GPR119GLP1RHTR1ACYP2C8KCNH2 | |
| SCHEMBL30798191 | 0.84 | PDE10A (0.43) | GPR119GLP1RPDE10A | |
| SCHEMBL27111216 | 0.83 | GPR119 (0.51) | GPR119GLP1RHTR1ACYP2C8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066338-A1 | CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2025-02-27 | — | — | US | disclosed |
| WO-2023111144-A1 | CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066338-A1 | CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS | GLP1R, GPR119, GIPR | GPR119 2/4885GLP1R 1/4885HTR1A 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.